Study of microbiome changes in patients with ulcerative colitis in the Central European part of Russia

Gryaznova, Mariya; Solodskikh, Sergey A.; Panevina, Anna V.; Syromyatnikov, Mikhail; Dvoretskaya, Yu.D.; Sviridova, Т.Н.; Попов, Е. С.; Popov, Vasily N.

doi:10.1016/j.heliyon.2021.e06432

Cited by 67 publications

(56 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings also demonstrated that, in addition to increasing the abundance of Akkermansia , crocetin significantly reduced the abundance of Muribaculaceae_unclassified , Duncaniella , and Eisenbergiella , which were negatively correlated with colitis severity [ 32 , 33 ]. We found members of the family Muribaculaceae (known as S24-7) in the guts of homoeothermic animals, where they were thought to play an important role in modulating the host’s health by degrading mucin [ 34 , 35 ].…”

Section: Discussionmentioning

confidence: 82%

Crocetin Prolongs Recovery Period of DSS-Induced Colitis via Altering Intestinal Microbiome and Increasing Intestinal Permeability

Feng

Liu

et al. 2022

IJMS

View full text Add to dashboard Cite

Crocetin is one of the major active constituents of saffron (Crocus sativus L.) which has a reputation for facilitating blood circulation and dispersing blood stasis in traditional Chinese medicine. However, there is little evidence showing the relationship between crocetin intake and the risk of gastrointestinal diseases such as colitis. In order to investigate the effect of crocetin on the regulation of intestinal barrier function and intestinal microbiota composition, mice were treated with crocetin after 3% dextran sulfate sodium (DSS) administration for one week. We found that crocetin intake at 10 mg/kg aggravated colitis in mice, showing increased weight loss and more serious histological abnormalities compared with the DSS group. The 16s rDNA sequencing analysis of the feces samples showed that mice treated with 10 mg/kg crocetin had lower species diversity and richness than those treated with DSS. At the genus level, a higher abundance of Akkermansia and Mediterraneibacter, and a lower abundance of Muribaculaceae, Dubosiella, Paramuribaculum, Parasutterella, Allobaculum, Duncaniella, Candidatus Stoquefichus, and Coriobacteriaceae UCG-002 were observed in the crocetin group. Untargeted metabolomic analyses revealed that crocetin reduced the levels of primary and secondary bile acids such as 12-ketodeoxycholic acid, 7-ketodeoxycholic acid, 3-sulfodeoxycholic acid, 6-ethylchenodeoxycholic acid, chenodeoxycholate, glycochenodeoxycholate-7-sulfate, glycocholate, and sulfolithocholic acid in the colon. In conclusion, crocetin intake disturbed intestinal homeostasis and prolonged recovery of colitis by promoting inflammation and altering gut microbiota composition and its metabolic products in mice. Our findings suggest that patients with gastrointestinal diseases such as inflammatory bowel disease should use crocetin with caution.

show abstract

Section: Discussionmentioning

confidence: 82%

Crocetin Prolongs Recovery Period of DSS-Induced Colitis via Altering Intestinal Microbiome and Increasing Intestinal Permeability

Feng

Liu

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Furthermore, in patients with ulcerative colitis in the central European part of Russia, there was a significant decrease in the genus of Fusicatenibacte . The current research showed that the supplementation of XOS could increase the level of Fusicatenibacter , which may be beneficial for the UC treatment ( 31 ). Additionally, the number of Lactococcus and Lactobacillu s, increased under the supplementation of XOS ( Figure 6 ).…”

Section: Discussionmentioning

confidence: 86%

Effects of Xylo-Oligosaccharide on the Gut Microbiota of Patients With Ulcerative Colitis in Clinical Remission

Zhu

et al. 2021

Front. Nutr.

View full text Add to dashboard Cite

Gut microbiota dysbiosis is closely associated with ulcerative colitis (UC). Prebiotic therapy is a potential approach for UC management especially remission maintaining. Xylo-oligosaccharide (XOS) is an efficient prebiotic with proven health benefits and few side effects. However, the effects of XOS on the gut microbiota of patients with UC have not been investigated previously. The aim of this study was to evaluate the prebiotic effects of XOS on the fecal microbiota of patients with UC in clinical remission using an in vitro fermentation model. Five patients with UC in clinical remission and five healthy volunteers were enrolled in this study. Fresh fecal samples of UC patients were diluted and inoculated in yeast extract, casitone and fatty acid (YCFA) medium alone or with XOS. After fermentation for 48 h, samples were collected for 16S rDNA sequencing to investigate the gut microbiota composition. Differences in the gut microbiota between healthy volunteers and UC patients in clinical remission were detected using original fecal samples. Subsequently, the differences between the YCFA medium alone or with XOS samples were analyzed to illustrate the effects of XOS on the gut microbiota of UC patients. In both principal coordinate analysis (PCoA) and principal component analysis (PCA), the fecal samples of UC patients differed from those of healthy volunteers. Linear discriminant analysis effect size (LEfSe) analysis revealed that the relative abundances of g_Roseburia and g_Lachnospiraceae_ND3007_group were higher in healthy volunteers than in UC patients, while o_Lactobacillales abundance showed the opposite trend (P < 0.05). Wilcoxon rank-sum test bar plot showed that the abundances of g_Eubacterium_halli_group and g_Lachnospiraceae_ND3007_group were higher in the healthy volunteers than in the UC patients (P < 0.05). In addition, in UC patients, the Wilcoxon rank-sum test showed that XOS fermentation promoted the growth of bacterial groups including g_Roseburia, g_Bifidobacterium, and g_Lactobacillus, which is beneficial for recovery of intestinal diseases. These results suggest that XOS can relieve dysbiosis in the feces of UC patients in clinical remission and thus represent a potential prebiotic material for maintaining remission.

show abstract

“…It produces the design matrix where elements indicate whether a sample j belongs to the experimental group (clinically healthy cows or the group with subclinical mastitis) or not. p values for each OTU were obtained using the Wald test [ 24 ].…”

Section: Methodsmentioning

confidence: 99%

Microbiota of Cow’s Milk with Udder Pathologies

et al. 2021

Self Cite

View full text Add to dashboard Cite

Mastitis is the most common disease for cattle, causing great economic losses for the global dairy industry. Recent studies indicate the multi-agent and microbiome diversity of this disease. To understand the nature of mastitis and investigate the role of the microbiome in the development of pathologies in the udder of bovines, we performed NGS sequencing of the 16S rRNA gene of cow’s milk with pathologies of the udder. The obtained data show a significant increase in the Cutibacterium, Blautia, Clostridium sensu stricto 2, Staphylococcus, Streptococcus and Microbacterium genera for groups of cows with udder pathologies. Increasing relative abundance of the Staphylococcus and Streptococcus genera was associated with subclinical mastitis. Our data show that a relative increase in abundance of the Staphylococcus and Microbacterium genera may be an early sign of infection. We have shown, for the first time, an increase in the Colidextribacter, Paeniclostridium and Turicibacter genera in groups of cows with mastitis. These results expand our understanding of the role of the microbiome in the development of bovine mastitis.

show abstract

Study of microbiome changes in patients with ulcerative colitis in the Central European part of Russia

Cited by 67 publications

References 55 publications

Crocetin Prolongs Recovery Period of DSS-Induced Colitis via Altering Intestinal Microbiome and Increasing Intestinal Permeability

Crocetin Prolongs Recovery Period of DSS-Induced Colitis via Altering Intestinal Microbiome and Increasing Intestinal Permeability

Effects of Xylo-Oligosaccharide on the Gut Microbiota of Patients With Ulcerative Colitis in Clinical Remission

Microbiota of Cow’s Milk with Udder Pathologies

Contact Info

Product

Resources

About